Drug development programs
Small Pharma’s pipeline of short-acting psychedelic programs is in development to address mental health indications where there is significant unmet need.
Our current progress across our R&D programs
The investigational product candidates listed here are not approved by the United States Food and Drug Administration (FDA), the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) or European Medicines Agency (EMA) and the safety and effectiveness is yet to be established.
Exploring DMT fumarate SPL026 with supportive therapy to treat Major Depressive Disorder. Small Pharma was awarded an Innovation Passport designation by the MHRA for this program, providing access to the ILAP (Innovative Licensing & Access Pathway) which aims to accelerate time to market.
An injectable formulation of deuterated DMT designed to deliver a more prolonged psychedelic experience.
Oral tryptamine series
An oral formulation of a tryptamine to offer an alternative way to deliver the treatment to patients in clinic.
Our current pipeline programs are based on psychedelic tryptamines including the short-acting compound DMT or N,N, dimethyltryptamine – a naturally occurring psychoactive molecule.  Amongst the family of tryptamine structures is serotonin. Other so-called “classical” psychedelics, such as psilocybin and 5-MeO-DMT, also have tryptamine-derived chemical structures. DMT targets a number of receptors in the brain, notably the 5-HT2A serotonin receptor.  Small Pharma is manufacturing synthetic drug candidates.